Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GB:0QYQ)
LSE:0QYQ
0QYQ Stock Chart & Stats
$121.94
-$1.41(-1.54%)
At close: 4:00 PM EST
$121.94
-$1.41(-1.54%)
Day’s Range― - ―
52-Week Range$86.11 - $125.48
Previous CloseN/A
Volume12.77K
Average Volume (3M)5.06K
Market Cap
$153.96B
Enterprise Value$157.48B
Total Cash (Recent Filing)$5.21B
Total Debt (Recent Filing)$24.95B
Price to Earnings (P/E)24.5
Beta0.42
Next Earnings
Oct 30, 2025EPS Estimate
2.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.01
Shares Outstanding1,240,806,900
10 Day Avg. Volume3,655
30 Day Avg. Volume5,063
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue5.46
Enterprise Value/Gross Profit6.95
Enterprise Value/Ebitda14.35
Forecast
1Y Price Target
$129.35Price Target Upside6.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
CDC GuidelinesThe US CDC recently updated its HIV pre-exposure prophylaxis (PrEP) guidelines and now recommends GILD's Yeztugo as an option, which is an incremental positive for the stock.
HIV Treatment MarketYeztugo physician survey shows strong initial trends in HIV prevention, with 92% reporting outcomes that met or exceeded expectations.
Patent StrategyThe settlement with Biktarvy generics is expected to delay generic entry until April 1, 2036, giving Gilead Sciences more time to maintain market exclusivity.
Bears Say
Price Negotiation RisksGilead Sciences' Biktarvy could potentially be included in the next group of drugs for IRA price negotiations, affecting future estimates.
Pricing Policy ImpactsThere is a potential impact on Gilead Sciences' revenue and EPS due to Medicaid-linked MFN pricing policy.
Stock ValuationThe stock is trading towards the top end of the peer group at a multiple of 12.6x the 2026 EPS estimate.
Gilead Sciences News
0QYQ FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest share price was $86.11 and its highest was $125.48 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $153.96B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Oct 30, 2025 which is in 7 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Aug 07, 2025. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences does not currently pay dividends.
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 2.15.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,240,806,900 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.01 in its last earnings report, beating expectations of $1.96. Following the earnings report the stock price went up 8.138%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GB:0QYQ
Gilead Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$129.35 (6.08% Upside)
$129.35 (6.08% Upside)
Blogger Sentiment
Bullish
GB:0QYQ Sentiment 90%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.87%
12-Months-Change
Fundamentals
Return on Equity
33.26%
Trailing 12-Months
Asset Growth
4.00%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
0QYQ Company Deck
0QYQ Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Gilead with significant achievements, including the FDA approval of Yeztugo and strong sales growth in the HIV segment. However, there are challenges with declining Veklury sales and competition in cell therapy, along with potential policy impacts. Overall, the highlights significantly outweigh the lowlights, indicating a strong position for Gilead moving forward.View all GB:0QYQ earnings summaries0QYQ Revenue Breakdown
68.21% HIV
11.44% Oncology
10.51% Liver Disease
6.26% Veklury
3.59% Other
0QYQ Stock 12 Month Forecast
Average Price Target
$129.35
▲(6.08% Upside)
Technical Analysis
Options Prices
Currently, No data available
---